Revenue segments as reported by the company.

Diabetes

Oncology

Immunology

Neuroscience

Other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Marketing, selling and administrative

Acquired in-process research and development

Asset impairment, restructuring and other special charges

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Eli Lilly

Cialis, ia a competitor to Pfizer's blockbuster Viagra for erectile dysfunction. Cialis maintains an active period of 36 hours.

Cialis

Cymbalta is a serotonin-norepinephrine reuptake inhibitor used predominantly in the treatment of major depressive disorders and generalized anxiety disorder, ranks with Prozac as one of the most financially successful pharmaceuticals in industry history. It is also used in the treatment of fibromyalgia, neuropathy, chronic pain and osteoarthritis.

Cymbalta

Gemzar is a treatment of pancreatic cancer. Gemzar is commonly used in the treatment of pancreatic cancer, usually in coordination with 5-FU chemotherapy and radiology. Gemzar also is routinely used in the treatment of non-small cell lung cancer.

Gemzar

Methadone is an analgesic used frequently in the treatment of heroin, opium and other opioid and narcotic drug addictions.

Methadone

Prozac was one of the first therapies in its class to treat clinical depression by blocking the uptake of serotonin within the human brain. It is prescribed to more than fifty-four million people worldwide.

Prozac

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Eli Lilly reports robust Q4 earnings, eyes growth in innovative therapies

Eli Lilly's Q4 2022 earnings call highlighted strong financial performance, pipeline advancements, and strategic initiatives for future growth.
The company's focus on innovation, FDA approvals, and market expansion underscores its commitment to addressing unmet medical needs and driving shareholder value.
Challenges in physician education, obesity treatment development, and market access present areas for strategic focus and investment for sustained growth.
Opportunities in expanding manufacturing capacity, engaging with payers, and capitalizing on consumer interest in obesity treatments position Lilly for continued success in 2023.

Eli Lilly reports robust Q1 growth amidst capacity challenges

Eli Lilly's Q1 2023 performance reflects strong revenue growth and strategic investments in new products and facilities.
While facing challenges in capacity and supply pressure, the company's focus on pipeline advancements and market opportunities positions it for future growth.
Opportunities in international markets, cardiovascular trials, and product promotion present avenues for continued expansion and revenue growth.
Overall, Eli Lilly's financial performance, product strengths, and strategic initiatives demonstrate a resilient and growth-focused approach.

Eli Lilly reports robust Q2 earnings, eyes growth through innovation

Eli Lilly's Q2 earnings call showcased strong financial performance, revenue growth, and advancements in its pipeline, driven by key products and strategic investments.
The company faces challenges in managing increased expenses, supply chain constraints, and regulatory considerations, requiring strategic decision-making and operational agility.
Opportunities lie in expanding market access, leveraging innovative treatments like tirzepatide, and enhancing manufacturing capabilities to drive future growth and competitive advantage.
Overall, Lilly's focus on innovation, market expansion, and addressing health needs positions it well for sustained growth and leadership in the pharmaceutical industry.

Eli Lilly posts robust Q3 results, eyes expansion and commercial growth

Eli Lilly (LLY) showcased strong financial performance and pipeline advancements in Q3 2023.
Challenges include supply restrictions and pricing decisions, but opportunities lie in expansion plans and commercial coverage ramp-up.
Investors advised to focus on guidance range for insights into 2024 expectations.

Eli Lilly posts robust Q4 results, eyes global expansion opportunities

Eli Lilly's strong financial performance in Q4 2023, driven by revenue growth and operational efficiency, sets a solid foundation for future growth.
The company's strategic acquisitions, global expansion plans, and focus on innovation position it well for continued success and market leadership.
Challenges in drug development and manufacturing require careful navigation, but opportunities in new drug trials and market expansion offer avenues for growth.
Overall, Eli Lilly's 2023 was marked by productivity and anticipation of sustained momentum in 2024, reflecting a positive outlook for the company.

Eli Lilly reports robust Q1 growth, eyes pipeline opportunities

Eli Lilly's Q1 performance showcased strong revenue growth, driven by new products and global market expansion.
While facing challenges like low Zepbound volume and manufacturing complexities, Lilly's strengths in innovation and market presence position it well for growth.
Opportunities in pipeline advancements, differentiation in drug portfolios, and potential Alzheimer's treatments signal a promising future for the company.
Overall, Eli Lilly's strategic focus on growth, innovation, and market expansion sets a positive trajectory for continued success.

Eli Lilly reports stellar Q3 results, eyes global expansion opportunities

Eli Lilly's Q3 performance reflects robust revenue growth, driven by new products and strategic investments, positioning the company for continued success.
Key pipeline advancements and revenue guidance raise optimism for future growth, with a focus on global scaling and market expansion initiatives.
Challenges in patient adherence and treatment efficacy are being addressed, while opportunities in market penetration and revenue growth are actively pursued.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

After years of a slowdown in performance and revenue, Eli Lilly (NYSE: LLY) is starting to turn the page. With its innovations in the pharmaceutical sector, most notably in diabetes treatment, its medications performed well, raking in a huge chunk of revenue and propelling this pharmaceutical giant to the 10th largest company by market cap.

This pharma stock is gearing up for a huge surge

Apple

Alphabet

Microsoft

Tesla

All five of these heavily-followed stocks soared by at least 48% last year. Analysts, though, don't expect any of them to rise by more than a single-digit percentage over the next 12 months.

These 5 Wildly Popular High-Flying Stocks of 2023 Could Be Duds in the Rest of 2024, According to Wall Street

Eli Lilly is the largest healthcare company by market capitalization. The company is unlikely to underperform its similarly-sized peers.

Prediction: This Will Be the First Trillion-Dollar Healthcare Stock

Eli Lilly just wrapped up a great year for shareholders, and there may be an encore in 2024. The company is going to continue its business development bonanza.

Here's What Investors Should Expect From Eli Lilly Stock in 2024

Eli Lilly has outperformed Meta Platforms in recent years. The biotech leader has excellent mid-term prospects.

Will Eli Lilly Be Worth More Than Meta Platforms by 2030?

CRISPR Therapeutics

Novo Nordisk

CRISPR Therapeutics stock has room to run higher with the biotech's first therapy on the market. Eli Lilly is now the world's biggest drugmaker and has multiple growth drivers.

3 High-Flying Stocks That Could Soar Even More in 2024

Eli Lilly and Company stock has delivered almost 5x returns in the past five years, with an almost 100% upsurge in the last 12 months alone. Eli Lilly's success is attributed to its focus on obesity/diabetes drugs, with currently available blockbusters like Mounjaro and Zepbound, and pipeline products Orforglipron and Retatrutide underpinning LT share gains. Paired with superior efficacy demonstrated in ongoing late-stage trials for oncology and neurodegeneration drugs, Eli Lilly demonstrates an adequately diversified portfolio for replicating its success in recent years.

Eli Lilly: The Cupboard Is Fully Stocked

U.S. inspectors recently uncovered new manufacturing problems at an Eli Lilly plant that has been under scrutiny by federal investigators, according to government records obtained by Reuters.

Exclusive: US FDA finds new manufacturing lapses at Eli Lilly plant

As is its habit, the pharmaceutical industry raised prices for a clutch of branded products at the start of the year. One popular medication seeing a price increase was Mounjaro.

Why Eli Lilly Stock Tumbled on Thursday

Gilead Sciences

Vertex Pharmaceuticals

For the past two years, biotech stocks have faced unfavorable conditions. These stocks have been on a downward spiral after reaching their pick at the beginning of 2021.

Bio-Revolution: 3 Biotech Stocks With Breakthrough Potential

Accenture Plc

Automatic Data Processing

ASML Hld

Booz Allen Hamilton Hld

Broadridge Financial

Cummins

Costco

Digital Realty Trust

Domino's Pizza

FedEx

Intuit

New Linde PLC

Mastercard

Moody's

Marsh & McLennan

MSCI

NIKE

Oracle

Parker-Hannifin

Rexford Industrial Realty

Roper Technologies

UnitedHealth Group

Visa

I make trades at the start of the new tax year to lock in gains and strengthen my portfolio. I focus on dividend growth stocks and have compiled a list of 25 stocks that I expect to provide double-digit dividend raises in 2024. I emphasize the importance of fundamental growth, stable balance sheets, and management dedication to shareholder returns when selecting dividend growth stocks.

25 Stocks With Double Digit Dividend Growth Potential In 2024

Eli Lilly (LLY) reachead $628.91 at the closing of the latest trading day, reflecting a -0.89% change compared to its last close.

Why Eli Lilly (LLY) Dipped More Than Broader Market Today

Novartis

As investors, our job isn't to predict an unknowable future.

These Stocks Are Showing Relative Strength as S&P 500 Stalls Near Record High

Health Care Select Sector SPDR Fund

AbbVie

Danaher

DexCom

McKesson

Viatris

Chart-watchers are growing increasingly bullish on health-care stocks now that they have become the best-performing sector of the S&P 500 so far in 2024, according to Dow Jones Market Data. Analysts have cited attractive valuations relative to earnings and a compelling growth story as two reasons health-care stocks might continue to outperform.

Charts turn bullish on health-care stocks as sector takes early lead in 2024

The top international executive at Eli Lilly on Tuesday said the pharmaceutical company will consider regulatory approvals, reimbursement and sufficient supplies before deciding whether to launch its weight-loss drug Mounjaro in new markets.

Lilly exec says supply, reimbursement are factors for new Mounjaro launches

Amazon

NVIDIA

Apple and Microsoft are battling it out to be the most valuable in the S&P 500. But analysts already predict who will be the winner.

Analysts Predict The 10 Most-Valuable Stocks In 12 Months

Clinical weight-loss medications have been making headlines. GLP-1 drugs like Novo Nordisk A/S NYSE: NVO owned Ozempic and Wegovy and Eli Lilly and Co. NYSE: LLY owned Mounjaro and Zepbound continue to see demand outstrip supply.

2 biotechs with promising weight-loss drugs coming

Not only did they hike their payouts, they did so at double-digit percentage rates. Eli Lilly is barging into 2024 with a newly approved medication that's sure to be a hit.

These 2 Top Healthcare Stocks Declared Dividend Raises in 2023

Ginkgo Bioworks Holdings

Eli Lilly's valuation is through the roof, but it's not just hot air. Ginkgo Bioworks could become a great long-term pickup.

3 Pricey Stocks I'll Be Watching Like a Hawk in 2024

Allstate

Arista Networks

Catalent

Intuitive Surgical

Merck

Palo Alto Networks

The S&P 500 rebounded last week near record highs, but is up just 0.2% so far in 2024. These are the index's top performers so far.

These 9 Stocks Are Running To Start 2024

News for Eli Lilly Stock (LLY)